The STELLAR Trial: Fluorescence-guided Surgery in Laryngeal- and Hypopharyngeal Cancer: a Feasibility Trial
Status: Recruiting
Location: See all (2) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
This is an open-label, single-dose, prospective clinical trial. The study comprises 2 work packages. The main objective of work package I (WP-1) is to assess feasibility of Fluorescence imaing (FLI) during total laryngectomy (TLE) and to assess the optimal dose of the cRGD-ZW800-1. Work package II (WP-II) is designed to assess whether FLI can detect and decrease tumor positive margins after a TLE.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Patients with biopsy-proven squamous cell Laryngeal and hypopharyngeal cancer, eligible for surgical resection of the tumor by TLE;
• ≥ 18 years of age;
• Written informed consent must be obtained;
• Sufficient knowledge of the Dutch language to understand the informed consent form;
Locations
Other Locations
Netherlands
Erasmus Medical Center
NOT_YET_RECRUITING
Rotterdam
Erasmus Medical Center
RECRUITING
Rotterdam
Time Frame
Start Date: 2026-03-31
Estimated Completion Date: 2028-03-31
Participants
Target number of participants: 27
Treatments
Experimental: 0.05 mg/kg cRGD-ZW800-1
n=3. Injection of 0.05 mg/kg cRGD-ZW800-1, within 2 hours before imaging/surgery
Experimental: 0.025 mg/kg cRGD-ZW800-1
n=3. Injection of 0.025 mg/kg cRGD-ZW800-1, within 2 hours before imaging/surgery
Experimental: 0.01 mg/kg cRGD-ZW800-1
n=3. Injection of 0.01 mg/kg cRGD-ZW800-1, within 2 hours before imaging/surgery.
Experimental: Expansion Cohort
n=18: expansion cohort will be added to the group of patients that had received the selected dose in WP-I.
Related Therapeutic Areas
Sponsors
Leads: Erasmus Medical Center